Evoke Pharma, Inc. reiterates revenue guidance for 2024. The company reiterated net revenue guidance in 2024 of approximately $14 million. Evokes 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.529 USD | +5.48% |
|
-13.28% | -49.63% |
28/05 | Evoke Pharma, Inc. Appoints Mark A. Kowieski as Chief Financial Officer | CI |
14/05 | Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.63% | 45.48L | |
+55.32% | 82TCr | |
+44.05% | 64TCr | |
-6.75% | 35TCr | |
+13.56% | 31TCr | |
+10.68% | 30TCr | |
+16.57% | 24TCr | |
+2.04% | 22TCr | |
+13.31% | 22TCr | |
+8.48% | 17TCr |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Evoke Pharma, Inc. Reiterates Revenue Guidance for 2024